2021 Revenues ($USD) : $3,554,748,000
2021 Revenues (foreign currencies) : € 3,118,200,000
2021 R&D spend : $454,632,000
2021 Number of Employees : 13,000
Fiscal Year End : 12/31/2020
Key People : Alexandre Mérieux, chairperson and CEO; Pierre Boulud, chief operating officer, clinical operations; Guillaume Bouhours, EVP, CFO, purchasing, information systems; Pierre Charbonnier, EVP, global quality, manufacturing and supply chain; François Lacoste, EVP, R&D; Valérie Leyldé, EVP, human resources and communications; Mark Miller, EVP, chief medical officer; Yasha Mitrotti, EVP, industrial microbiology; Esther Wick, EVP, legal, IP and compliance.

About the company: An important player in the in vitro diagnostics space for more than 55 years, BioMérieux has a presence in 44 countries and serves more than 160 countries with the support of large distributors. The company provides a wide range of diagnostic systems, reagents, software and services to detect diseases and contamination, improve people’s health, and bolster consumer safety. An upturn in U.S. respiratory panels demand amid the COVID-19 Delta variant wave pushed sales up 12% through the first nine months of 2021. In October, BioMérieux and Baxter announced CE mark approval for their Nephroclear CCL14 test to predict persistent severe acute kidney injury. –CN